Advances in pediatric infectious diseases最新文献_第3页

Pertussis in older children and adults. 大龄儿童和成人百日咳。

Advances in pediatric infectious diseases Pub Date : 1997-01-01

K M Edwards

引用次数: 0

Controversies in Kawasaki syndrome. 川崎综合征的争议。

Advances in pediatric infectious diseases Pub Date : 1997-01-01

A H Rowley

引用次数: 0

Vancomycin resistant enterococci: impact and management in pediatrics. 万古霉素耐药肠球菌:在儿科的影响和处理。

Advances in pediatric infectious diseases Pub Date : 1997-01-01

M Green

引用次数: 0

Human parvovirus B19 infections in infants and children. 婴儿和儿童的人细小病毒B19感染。

Advances in pediatric infectious diseases Pub Date : 1997-01-01

K E Brown, N S Young

引用次数: 0

Neisseria meningitidis in the 1990s. 脑膜炎奈瑟菌。

Advances in pediatric infectious diseases Pub Date : 1997-01-01

W J King, N E MacDonald

引用次数: 0

Foodborne and waterborne illness in children. 儿童食源性和水传播疾病。

Advances in pediatric infectious diseases Pub Date : 1996-01-01

I R Rivera-Matos, T G Cleary

引用次数: 0

Viral hemorrhagic fevers. 病毒性出血热。

Advances in pediatric infectious diseases Pub Date : 1996-01-01

M D Lacy, R A Smego

引用次数: 0

Tularemia. 兔热病。

Advances in pediatric infectious diseases Pub Date : 1996-01-01

R F Jacobs

引用次数: 0

Malaria in children. 儿童疟疾。

Advances in pediatric infectious diseases Pub Date : 1996-01-01

R W Steele

引用次数: 0

Antiretroviral therapy: evaluating the new era in HIV treatment. 抗逆转录病毒治疗:评价艾滋病毒治疗的新时代。

Advances in pediatric infectious diseases Pub Date : 1996-01-01

R E McKinney

{"title":"Antiretroviral therapy: evaluating the new era in HIV treatment.","authors":"R E McKinney","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Tools for evaluating antiretroviral therapy are still evolving. Key components are available such as the laboratory assays themselves, but results from these assays are being analyzed and presented inconsistently, making interstudy comparisons difficult or impossible. In part, the problems in analysis and presentation reflect a lack of completed clinical trials in which new laboratory methods such as RNA copy numbers can be validated. Survival is the clearest valid end point in clinical trials of antiretroviral drugs. Beyond life and death, the next most important issue is quality of life. Because of the difficulty in agreeing what \"quality of life\" means, and the even greater problems measuring such an abstract concept, in most cases assessments are made of more quantifiable clinical elements: cognitive and motor function, growth, and the frequency of opportunistic infections. Laboratory markers of disease progression are very quantifiable but have meaning only when they predict clinical outcome. There is a consensus that CD4+ counts, CD4+ percentages, and HIV copy numbers measured by RNA PCR are important. There is not, however, a consensus approach to interpretation of data from any of these markers of HIV disease, particularly because the interpretation may vary based on the patient's level of clinical disease. With time and more clinical trials with which to clarify their use, these tools should become more uniformly applied, at which point cross-study comparisons might be possible. Progress is already being made in the development of new antiretroviral therapies, and with improved evaluation techniques the evolution of new anti-HIV treatments should become an even more efficient process.</p>","PeriodicalId":76980,"journal":{"name":"Advances in pediatric infectious diseases","volume":"12 ","pages":"297-323"},"PeriodicalIF":0.0,"publicationDate":"1996-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19991159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0